Relmada Therapeutics Company Profile (NASDAQ:RLMDD)

Analyst Ratings

Consensus Ratings for Relmada Therapeutics (NASDAQ:RLMDD) (?)
Ratings Breakdown: 1 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $7.00 (48.31% upside)

Analysts' Ratings History for Relmada Therapeutics (NASDAQ:RLMDD)
Show:
DateFirmActionRatingPrice TargetActions
9/3/2015FBR & CoInitiated CoverageMarket Perform$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Relmada Therapeutics (NASDAQ:RLMDD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Relmada Therapeutics (NASDAQ:RLMDD)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Relmada Therapeutics (NASDAQ:RLMDD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Relmada Therapeutics (NASDAQ:RLMDD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Relmada Therapeutics (NASDAQ:RLMDD)
DateHeadline
06/25/16 09:52 AMRelmada Therapeutics Inc (OTCMKTS:RLMD) Slips Again
06/09/16 09:08 AMRelmada Therapeutics' d-Methadone gets US FDA orphan drug status for management of PHN
04/14/16 09:10 AMAnalysts' Downgrades for April, 14th (DLAR, IWSY, JOB, JRVR, JTPY, JYNT, KHNGY, KNL, LBRDA, LC) - Washington News Wire - Analysts' Downgrades for April, 14th (DLAR, IWSY, JOB, JRVR, JTPY, JYNT, KHNGY, KNL, LBRDA, LC)Washington News WireRelmada Therapeutics (NASDAQ:RLMDD) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company.and more »
09/09/15 07:00 AMRelmada Therapeutics Announces Issuance of U.S. Patent Covering SECUREL™ - an Abuse-Deterrent, Extended-Release, Technology Platform for Opioids - [PR Newswire] - NEW YORK, Sept. 9, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that U.S. Patent ...
09/02/15 07:00 AMRelmada Therapeutics to Participate in Two Upcoming Investor Conferences - [PR Newswire] - NEW YORK, Sept. 2, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD; RLMDD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the ...

Social

About Relmada Therapeutics

Relmada Therapeutics logo

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RLMDD
  • CUSIP:
Key Metrics:
  • Previous Close: $4.72
  • 50 Day Moving Average: $3.11
  • 200 Day Moving Average: $5.64
  • P/E Ratio: 9.22
  • P/E Growth: 0.00
  • Market Cap: $56.64M
  • Current Year EPS Consensus Estimate: $-1.40 EPS
  • Next Year EPS Consensus Estimate: $-2.11 EPS
Additional Links:
Relmada Therapeutics (NASDAQ:RLMDD) Chart for Thursday, July, 28, 2016